Indaptus Therapeutics, Inc.
Formerly INTEC PARENT, INC.
Indaptus Therapeutics, Inc. is listed today as Indaptus Therapeutics, Inc.: market value, financials and filings are on its company page.
Funding rounds
0 counted as startup funding, 3 other private sales on record. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Jun 2025 | $2 M | Private placement after listing | $2 to $10 million | options | SEC | |
| Jan 2025 | $2 M | Private placement after listing | $2 to $10 million | equity, options | SEC | |
| Jul 2021 | $30 M | Issued in a merger or acquisition | $10 to $50 million | options | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
Indaptus Therapeutics, Inc. chose not to state its revenue in its newest notice of a funding round (Jun 2025).
SEC Form D · Jun 2025
The industry group it chose in its notices: Pharmaceuticals.
SEC Form D · Jun 2025
That is all the official record says: Indaptus Therapeutics, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.
Products and services#
No products or services of Indaptus Therapeutics, Inc. are on record.
Investors#
1 named in official filings. Open an investor to see everything it has backed.
| Investor | Kind | Amount | Round | Role | Source |
|---|---|---|---|---|---|
| David E. Lazar | Person | not stated | not stated | Held Series AA and AAA preferred stock (Form 3, 2025) | SEC Form 3 |
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete.
Largest shareholders today
Institutions holding Indaptus Therapeutics, Inc. shares, as of Sep 30, 2026.
- Geode Capital Management, LLC$0 M0.15%
- Vanguard Capital Management LLC$0 M0.10%
- Jane Street Group, LLC$0 M0.06%
- UBS Group AG$0 M0.06%
- Marshall Wace, LLP$0 M0.06%
- Millennium Management LLC$0 M0.05%
- Vanguard Fiduciary Trust Co$0 M0.05%
- State Street Corp$0 M0.05%
- Virtu Financial LLC$0 M0.03%
- Jump Financial, LLC$0 M0.02%
- Northern Trust Corp$0 M0.02%
- ExodusPoint Capital Management, LP$0 M0.01%
- Qube Research & Technologies Ltd$0 M0.01%
- Goldman Sachs Group Inc$0 M0.01%
- Barclays PLC$0 M0.01%
Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Jeffrey A. Meckler | Executive officer | Jun 2025 |
| Michael J Newman | Executive officer | Jun 2025 |
| Nir J Sassi | Executive officer | Jun 2025 |
| Roger J. Waltzman | Executive officer | Jun 2025 |
| Walt A. Linscott | Executive officer | Jun 2025 |
| Michael J. Newman | Executive officer | Jan 2025 |
| Nir A Sassi | Executive officer | Jan 2025 |
| Walt A Linscott | Executive officer | Jan 2025 |
| Michael A Newman | Executive officer | Aug 2021 |
| Anthony J. Maddaluna | Director | Jun 2025 |
| Hila J. Karah | Director | Jun 2025 |
| Jeffrey A. Meckler | Director | Jun 2025 |
| Mark J. Gilbert | Director | Jun 2025 |
| Michael J Newman | Director | Jun 2025 |
| Robert E. Martell | Director | Jun 2025 |
| Roger J. Pomerantz | Director | Jun 2025 |
| William B. Hayes | Director | Jun 2025 |
| Mark J Gilbert | Director | Jan 2025 |
| Michael J. Newman | Director | Jan 2025 |
| Brian J. O'Callaghan | Director | Aug 2021 |
| Hila W. Karah | Director | Aug 2021 |
| Hoonmo A Lee | Director | Aug 2021 |
| Michael A Newman | Director | Aug 2021 |
Went public since 2021. Its SEC number is that of a company listed on a stock exchange.